“India will make cheap lifesaving drugs available to developing nations”

In conversation, Anand Sharma, commerce and industry minister

bhavdeepkang

Bhavdeep Kang | March 8, 2013




The Intellectual Property Appellate Board of India on March 4 rejected the German firm Bayer AG's appeal of a ruling last year that allowed Hyderabad-based Natco Pharma to produce a cheaper generic version of Bayer’s kidney and liver cancer drug Nexavar. This would result in a treatment that more people would be able to afford. Our cover story for September 1-15, 2012 issue went behind the scenes to narrate how the initiatives of policymakers brought about this welcome change. In light of the latest ruling, we revisit that cover story.

Commerce and industry minister Anand Sharma did a tightrope walk in balancing commercial interests and ethical concerns – and all that was handled away from the limelight. Speaking with Bhavdeep Kang, Sharma shared his views on the pharma debates of our times. Excerpts from the interview:

How do you look at the compulsory licence granted for a cancer medicine?
In India, the compulsory licence has been given for the first time. The decision is in line with the TRIPS agreement and in conformity with our own law on patents. During the GATT (general agreement on trade and tariffs) negotiations, India took a firm stand on TRIPS and insisted on flexibility to ensure availability of lifesaving drugs at reasonable prices and this was agreed, as a way forward, to resolve the matter. This flexibility has been invoked by developing countries 63 times. In 2007, president Lula of Brazil made a similar intervention for HIV treatment.

Tell us about the government’s initiatives to bring down prices of lifesaving and other essential drugs.
The issue of access to lifesaving drugs has been occupying our attention for some time. The ethical debate on the subject has been going on since the late 1990s. The pharmaceutical industry mounted a legal challenge, but right ethics prevailed.

Also read: “Compulsory licence would be a trendsetter”

‘Cheaper drugs for the poor’ is a worldwide concern. Can India take leadership among the developing countries on this front?
Indian pharmaceuticals made a notable contribution and changed the discourse in terms of generic drugs, by making ARVs (antiretroviral drugs for HIV/Aids) available at low prices. Costs of treatment have dropped sharply, from $13,000 to $400 in some cases. Now, the new generation of ARVs must be made available, not only to us but to other developing and poor countries, at reasonable prices.

India will make available new generations of lifesaving drugs at reasonable prices to developing nations worldwide. For example, we have a malaria buster – an answer to drug resistant malaria developed for Africa.

Making lifesaving drugs available at reasonable prices is the duty of every state. Even in the US, healthcare and insurance are part of the national discourse. Earlier this year, the US FDA (food and drug authority) asked an Indian company (Sun Pharma) to produce Lipodox, a drug for treating ovarian cancer, to overcome drug shortages.

[This interview appeared in the September 1-15 issue of Governance Now.]

Comments

 

Other News

Maharashtra FDA cracks down on `health supplements`; seizes stock worth Rs 1.39 cr

The Maharashtra Food and Drug Administration (FDA) has issued a comprehensive state wide compliance order tightening regulations governing health supplements, nutraceuticals, sports nutrition products and foods for special dietary and medical purposes. The order, issued by Commissioner of Food Safety, Tu

States face rising fiscal pressure as spending outpaces revenue

States across India are facing increasing fiscal pressures, with revenue expenditure growing faster than revenue receipts since 2022-23, largely driven by rising subsidies and transfers, according to the annual ‘State of State Finances 2026-27’ report released by PRS Legislative Research.

Global value chains and sustainability

When a country’s factories become part of global supply chains, making parts or products that feed into goods sold around the world, the economy usually looks stronger. Output rises, exports grow, and technology improves. But the research behind this article [Bhayana and Nag, 2026] asks a harder qu

Narrative sovereignty in the digital age

In today’s world, competition between countries is not limited to military strength or economic power. It also takes place through the stories countries tell about themselves and the way others describe them. Social media and digital platforms have made this competition faster and more visible. Whe

The hidden cost of voter-ID link with welfare

On October 30, panchayati raj minister Rajiv Ranjan Singh, better known as Lalan Singh, told a national workshop in Delhi that Aadhaar would no longer be the basis for government schemes. His argument seemed simple enough. Aadhaar centres are now in every locality, and anyone can get a card made for anyb

The silent epidemic in the Northeast

In Mizoram, more than nine in ten people can read. Anyone there can find out how HIV spreads and how to protect themselves. Yet Mizoram has the highest rates of HIV patients in the country. If education were enough, this would’ve been solved long ago, but it was not. The answer tells us something a

Upcoming Conferences



-->

Archives

Current Issue

Opinion

Facebook Twitter Google Plus Linkedin Subscribe Newsletter

Twitter